RegulatoryGuideline · final

FDA finalises Q&A guidance on postapproval manufacturing changes for biosimilars and interchangeable biosimilars

🇺🇸 FDA · Tue 13 Oct 2026

The US regulator has issued the final version of its question-and-answer guidance on manufacturing changes made after licensure of biosimilar and interchangeable biosimilar products.

The US Food and Drug Administration has announced the availability of a final guidance for industry titled "Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products: Questions and Answers". The notice is dated 13 October 2026.

The document answers commonly asked questions from applicants and other interested parties about manufacturing changes made after approval. It covers biosimilar and interchangeable biosimilar products licensed under the Public Health Service Act (PHS Act).

The guidance finalises a draft of the same title that FDA issued on 23 July 2024. The summary on file does not describe what, if anything, changed between the draft and the final text, and the full guidance text was not available for this report.

As context, final FDA guidance documents represent the agency's current thinking on a topic. They are not legally binding but are widely used by sponsors to shape regulatory submissions.

What it means for your team

  • Regulatory affairs teams handling licensed biosimilars or interchangeable biosimilars should obtain the final guidance and check it against current postapproval change-management procedures.
  • Teams that tracked the July 2024 draft should compare it with the final version to identify any differences, as the summary does not specify them.
  • Quality and CMC functions may wish to review how planned manufacturing changes are assessed and documented in light of the Q&A format.

Official guideline text: FDA ↗

Article written by VigiEye from the official source (FDA). AI-assisted; check the source before acting.

More Regulatory All →